TNSN06384A1 - Indazoles substitues, compositions les contenant, procede de fabrication et utilisation - Google Patents

Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Info

Publication number
TNSN06384A1
TNSN06384A1 TNP2006000384A TNSN06384A TNSN06384A1 TN SN06384 A1 TNSN06384 A1 TN SN06384A1 TN P2006000384 A TNP2006000384 A TN P2006000384A TN SN06384 A TNSN06384 A TN SN06384A TN SN06384 A1 TNSN06384 A1 TN SN06384A1
Authority
TN
Tunisia
Prior art keywords
manufacture
compositions containing
indazoles
containing same
substituted indazoles
Prior art date
Application number
TNP2006000384A
Other languages
English (en)
Inventor
Franck Halley
Michel Tabart
Herve Bouchard
Catherine Souaille
Brun Alain Le
Fabrice Viviani
Laurence Gauzy-Lazo
Pascal Desmazeau
Odile Angouillant-Boniface
Bruno Filoche-Romme
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34946329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TNSN06384A1 publication Critical patent/TNSN06384A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Indazoles substitués, compositions les contenant, procédé de fabrication et utilisation. La présente invention concerne en particulier de nouveaux indazoles substitués spécifiques présentant une activité inhibitrice de kinases, ayant une activité thérapeutique, en particulier en oncologie.
TNP2006000384A 2004-06-04 2006-11-24 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation TNSN06384A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406042A FR2871158A1 (fr) 2004-06-04 2004-06-04 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PCT/FR2005/001335 WO2006003276A1 (fr) 2004-06-04 2005-06-01 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
TNSN06384A1 true TNSN06384A1 (fr) 2008-02-22

Family

ID=34946329

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000384A TNSN06384A1 (fr) 2004-06-04 2006-11-24 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Country Status (22)

Country Link
US (1) US7517902B2 (fr)
EP (1) EP1765813A1 (fr)
JP (1) JP2008501669A (fr)
KR (1) KR20070043769A (fr)
CN (1) CN1980918A (fr)
AR (1) AR049389A1 (fr)
AU (1) AU2005259139B2 (fr)
BR (1) BRPI0510777A (fr)
CA (1) CA2567744A1 (fr)
CR (1) CR8767A (fr)
EA (1) EA012702B1 (fr)
EC (1) ECSP067046A (fr)
FR (1) FR2871158A1 (fr)
IL (1) IL179595A0 (fr)
MA (1) MA28664B1 (fr)
MX (1) MXPA06013954A (fr)
NO (1) NO20066050L (fr)
TN (1) TNSN06384A1 (fr)
TW (1) TW200610756A (fr)
UY (1) UY28941A1 (fr)
WO (1) WO2006003276A1 (fr)
ZA (1) ZA200610040B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102006005179A1 (de) * 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2010505962A (ja) * 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2120932B1 (fr) 2006-12-20 2014-07-09 Nerviano Medical Sciences S.r.l. Dérivés de l'indazole en tant qu'inhibiteurs des kinases pour le traitement du cancer
PL2176231T3 (pl) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2791613A1 (fr) * 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Composes d'indazole et leurs utilisations
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
WO2014063068A1 (fr) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3233840B1 (fr) 2014-12-16 2018-11-21 Eudendron S.r.l. Dérivés hétérocycliques modulant l'activité de certaines protéines kinases
EP3236959A4 (fr) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
CN106032359B (zh) * 2015-03-09 2018-07-20 复旦大学 吲唑类化合物及其制备方法和用途
CA2978518C (fr) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibiteurs de kinases cycline-dependantes
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dependantes
WO2017106492A1 (fr) 2015-12-18 2017-06-22 Ignyta, Inc. Combinaisons pour le traitement du cancer
PE20190657A1 (es) 2016-09-23 2019-05-08 Novartis Ag Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CA3050770C (fr) * 2016-12-07 2023-09-12 Nanjing Xin Shi Dai Meditech Co. Ltd. Composes et compositions pharmaceutiques pour moduler l'activite sgk, et leurs procedes
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
WO2019018562A1 (fr) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. Composé amido utilisés comme modulateurs du ahr
EP3697390A1 (fr) 2017-10-17 2020-08-26 Ignyta, Inc. Compositions pharmaceutiques et formes galéniques solides
CN109134451A (zh) * 2018-09-10 2019-01-04 遵义医学院 1,3-二取代脲类与硫脲类衍生物及其应用
US20220388964A1 (en) * 2019-04-12 2022-12-08 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
CN114276297A (zh) * 2020-10-15 2022-04-05 兰州大学 一种1h-吲唑vegfr-2激酶抑制剂及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
WO2002100833A1 (fr) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003051847A1 (fr) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Derives de (1-h-indazol-3-yl) -amide comme inhibiteurs de gsk-3
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
CA2486101C (fr) * 2002-05-17 2009-07-07 Pharmacia Italia S.P.A. Derives d'aminoindazole agissant comme inhibiteurs de kinase, methode d'obtention et compositions pharmaceutiques les renfermant
CA2495216A1 (fr) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
JP4648703B2 (ja) 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
BR0316606A (pt) * 2002-12-12 2005-10-11 Aventis Pharma Sa Derivados de aminoindazóis e sua utilização como inibidores de quinases
SI1638941T1 (sl) * 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP1863766B1 (fr) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Amides substitues, procede pour les produire et procede pour les utiliser

Also Published As

Publication number Publication date
ECSP067046A (es) 2006-12-29
UY28941A1 (es) 2005-12-30
BRPI0510777A (pt) 2007-11-20
AU2005259139A1 (en) 2006-01-12
NO20066050L (no) 2007-02-05
CR8767A (es) 2007-08-28
ZA200610040B (en) 2008-02-27
EA200602241A1 (ru) 2007-04-27
EP1765813A1 (fr) 2007-03-28
KR20070043769A (ko) 2007-04-25
TW200610756A (en) 2006-04-01
US20070161626A1 (en) 2007-07-12
AU2005259139B2 (en) 2011-09-08
MA28664B1 (fr) 2007-06-01
US7517902B2 (en) 2009-04-14
EA012702B1 (ru) 2009-12-30
FR2871158A1 (fr) 2005-12-09
CN1980918A (zh) 2007-06-13
IL179595A0 (en) 2007-05-15
MXPA06013954A (es) 2007-03-15
JP2008501669A (ja) 2008-01-24
CA2567744A1 (fr) 2006-01-12
WO2006003276A1 (fr) 2006-01-12
AR049389A1 (es) 2006-07-26

Similar Documents

Publication Publication Date Title
TNSN06384A1 (fr) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TNSN04175A1 (fr) Indazoles substitues avec une activite anticancereuse
MXPA06011046A (es) Ciertos compuestos basados en triazol, composiciones, y usos de los mismos.
ATE378337T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
TW200733453A (en) Method of using an electrochemical cell
FR10C0037I2 (fr) Composes chimiques
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
TW200801008A (en) Protein kinase inhibitors
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
DE60228103D1 (de) Chemische verbindungen
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
NO20041493L (no) Kjemiske forbindelser.
DE602004027490D1 (de) Indazol-, benzisoxazol- und benzisothiazol-kinaseinhibitoren
ATE554087T1 (de) Neue kinaseinhibitoren
BRPI0414599A (pt) pirrol-indóis substituìdos
ECSP045255A (es) Cumarinas utiles como biomarcadores
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
MA30972B1 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2004069160A3 (fr) Composes chimiques
WO2006060542A3 (fr) Formulations de benzoxazoles substitues